AbbVie's earnings expected to drop

Today's Big News

Apr 6, 2023

Quince adopts 'poison pill' to fend off buyout bid as investor builds stake


'Like salmon swimming upstream': FDA's Peter Marks lays out plan to boost gene therapy approvals


AbbVie knocks down earnings forecast due to IPR&D charge


Exelixis defends strategy after activist investor calls R&D plan undisciplined and incoherent


A viral factory replicates human adenoviruses opposite to how an 'old-fashioned milk assembly line' works

 

Featured

Quince adopts 'poison pill' to fend off buyout bid as investor builds stake

Quince Therapeutics is trying to make itself a less appetizing bite for potential buyers as it works to fend off an unsolicited buyout bid from Echo Lake Capital. The “poison pill” is intended to deter investors from accumulating stock on the open market and will kick in once they buy a set percentage of the shares.
 

Top Stories

'Like salmon swimming upstream': FDA's Peter Marks lays out plan to boost gene therapy approvals

The FDA has approved 12 gene therapies so far, and the agency's top drug regulator wants to see the road ahead illuminated with green lights.

AbbVie knocks down earnings forecast due to IPR&D charge

AbbVie is revising down its earnings forecast for the year due to a $150 million IPR&D charge. The company's original earnings projections presented in February were already lower than Wall Street's projections.

Exelixis defends strategy after activist investor calls R&D plan undisciplined and incoherent

Exelixis is standing its ground in the face of a full-throated attack by an activist investor, defending its record in response to accusations that it has presided over an undisciplined and incoherent R&D model.

A viral factory replicates human adenoviruses opposite to how an 'old-fashioned milk assembly line' works

How exactly are baby human adenoviruses born? Scientists have wondered about this question for a long time, and new research published this week in Nature revealed the process that viral proteins use to replicate—which could lead to better gene therapy delivery and other new therapeutics.

ConcertAI debuts latest clinical trial software upgrade to improve studies

ConcertAI, which specializes in software and real-world evidence for clinical trials, has unveiled the latest version of its clinical trial optimization product.

Bioventus unseats CEO as CartiHeal deal falls apart

Almost exactly three years after taking on the role, Ken Reali has stepped down from his post as chief executive of Bioventus.

Thermo Fisher Scientific pulls plug on New Jersey biologics site, lays off 113

Thermos Fisher Scientific plans to close its Princeton, New Jersey, plant and lay off 113 workers. The company is making the move to “remain in line with current manufacturing volume demands," a spokesperson said.

Money continues to flow for HeartFlow with $215M VC raise

After reversing course on a SPAC deal last year, cardiac diagnostic developer HeartFlow has picked up what could hardly be considered a consolation prize.

GSK will have to pay additional royalties to AstraZeneca on cancer drug Zejula

After losing a patent case in court on Wednesday, GSK will have to surrender a portion of its sales of its ovarian cancer drug Zejula to AstraZeneca. The case involves technology GSK subsidiary Tesaro licensed from AZ 11 years ago.

Study: Cuts to Medicare Advantage payments may have modest impact on seniors' benefits

A new study in Health Affairs finds a decline in Medicare Advantage payments would only lead to a modest impact on benefits for seniors.
 
Fierce podcasts

Don't miss an episode

'The Top Line': The financial trends biotechs could face in 2023, plus this week's headlines

This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines.
 

Resources

Whitepaper

The Hematopoietic Colony Forming Cell (CFC) Assay for Drug Safety and Toxicity

The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process

Whitepaper

Accessing and Analyzing Relevant Content in Today’s Information Chaos – R&D Challenges and Opportunities

We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing?

Whitepaper

Blueprint for Commercializing Cell and Gene Therapies

How advanced medicines commercial readiness differs and the resources needed to maximize potential.

Whitepaper

Coming to America: Keys to Success for ex-US Digital Health Companies Entering the US Market

This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market.
Whitepaper

Plan for scalable process liquid and buffer preparation

Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation.

Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
 

Industry Events

 

Upcoming Fierce Events

1-3
May
May 1-3, 2023 | Jersey City, NJ
12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event

View all events